
INSM
Insmed Inc
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
105.080
Open
103.930
VWAP
104.07
Vol
1.40M
Mkt Cap
19.72B
Low
103.200
Amount
145.21M
EV/EBITDA(TTM)
--
Total Shares
163.12M
EV
19.65B
EV/OCF(TTM)
--
P/S(TTM)
46.95
Insmed Incorporated is a global biopharmaceutical company. The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines as well as drug discovery. Its advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company’s pre-clinical research programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Its first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib, TPIP, and INS1201 as well as pre-clinical research programs.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
152.44M
+45.96%
--
--
113.94M
+21.96%
--
--
103.66M
+14.74%
--
--
Estimates Revision
The market is revising Downward the revenue expectations for Insmed Incorporated (INSM) for FY2025, with the revenue forecasts being adjusted by -0.62% over the past three months. During the same period, the stock price has changed by 48.80%.
Revenue Estimates for FY2025
Revise Downward

-0.62%
In Past 3 Month
Stock Price
Go Up

+48.80%
In Past 3 Month
17 Analyst Rating

6.48% Upside
Wall Street analysts forecast INSM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INSM is 110.69 USD with a low forecast of 90.00 USD and a high forecast of 124.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
17 Buy
0 Hold
0 Sell
Strong Buy

6.48% Upside
Current: 103.950

Low
90.00
Averages
110.69
High
124.00

6.48% Upside
Current: 103.950

Low
90.00
Averages
110.69
High
124.00
Wells Fargo
Tiago Fauth
Overweight
maintain
$119 -> $130
2025-07-22
New
Reason
Wells Fargo
Tiago Fauth
Price Target
$119 -> $130
2025-07-22
New
maintain
Overweight
Reason
Wells Fargo analyst Tiago Fauth raised the firm's price target on Insmed to $130 from $119 and keeps an Overweight rating on the shares. While literature directly linking NSP inhibition to clinical endpoints in CRSsNP is lacking, the firm sees merit in the approach and views the risk/reward as attractive, given low investor expectations and a meaningful market opportunity.
Morgan Stanley
Maxwell Skor
Overweight
maintain
$102 -> $108
2025-07-16
Reason
Morgan Stanley
Maxwell Skor
Price Target
$102 -> $108
2025-07-16
maintain
Overweight
Reason
Morgan Stanley analyst Maxwell Skor raised the firm's price target on Insmed to $108 from $102 and keeps an Overweight rating on the shares as part of a Q2 earnings preview. The firm continues to view the potential brensocatib launch favorably. It cites increasing confidence into the potential bronchiectasis launch for the target bump.
JPMorgan
NULL
to
Overweight
upgrade
$90 -> $115
2025-07-08
Reason
JPMorgan
Price Target
$90 -> $115
2025-07-08
upgrade
NULL
to
Overweight
Reason
JPMorgan raised the firm's price target on Insmed to $115 from $90 and keeps an Overweight rating on the shares. After meeting with management, the firm believes Insmed is on a "strong trajectory." It expects an on-time brensocatib approval in August.
JPMorgan
Overweight
upgrade
$90 -> $111
2025-07-08
Reason
JPMorgan
Price Target
$90 -> $111
2025-07-08
upgrade
Overweight
Reason
JPMorgan raised the firm's price target on Insmed to $111 from $90 and keeps an Overweight rating on the shares. After meeting with management, the firm believes Insmed is on a "strong trajectory." It expects an on-time brensocatib approval in August.
Stifel
Stephen Willey
Buy
maintain
$92 -> $110
2025-06-11
Reason
Stifel
Stephen Willey
Price Target
$92 -> $110
2025-06-11
maintain
Buy
Reason
H.C. Wainwright
H.C. Wainwright
Buy
maintain
$90 -> $120
2025-06-11
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$90 -> $120
2025-06-11
maintain
Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Insmed Inc (INSM.O) is -20.54, compared to its 5-year average forward P/E of -8.92. For a more detailed relative valuation and DCF analysis to assess Insmed Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-8.92
Current PE
-20.54
Overvalued PE
-4.61
Undervalued PE
-13.23
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
-10.13
Current EV/EBITDA
-22.53
Overvalued EV/EBITDA
-5.56
Undervalued EV/EBITDA
-14.71
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Strongly Overvalued
5Y Average PS
16.51
Current PS
36.40
Overvalued PS
25.34
Undervalued PS
7.69
Financials
Annual
Quarterly
FY2025Q1
YoY :
+22.94%
92.82M
Total Revenue
FY2025Q1
YoY :
+46.02%
-229.84M
Operating Profit
FY2025Q1
YoY :
+63.33%
-256.58M
Net Income after Tax
FY2025Q1
YoY :
+33.96%
-1.42
EPS - Diluted
FY2025Q1
YoY :
+44.22%
-272.16M
Free Cash Flow
FY2025Q1
YoY :
+0.68%
75.72
Gross Profit Margin - %
FY2025Q1
YoY :
+11.04%
-207.14
FCF Margin - %
FY2025Q1
YoY :
+32.85%
-276.42
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
60.9M
USD
41
3-6
Months
37.6M
USD
25
6-9
Months
18.2M
USD
31
0-12
Months
25.6M
USD
8
Bought
0-3
2
201.7K
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
310.2K
Volume
4
6-9
Months
2.4M
Volume
12
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
8
2.5M
Volume
Months
6-9
10
4.8M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
8.0K
USD
1
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
1
8.0K
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
60.9M
USD
41
3-6
Months
37.6M
USD
25
6-9
Months
18.2M
USD
31
0-12
Months
25.6M
USD
8
Bought
0-3
2
201.7K
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
INSM News & Events
Events Timeline
2025-06-12 (ET)
2025-06-12
05:56:57
Insmed 7.812M share Spot Secondary priced at $96.00

2025-06-11 (ET)
2025-06-11
16:06:16
Insmed announces $650M common stock offering

2025-06-10 (ET)
2025-06-10
08:54:38
Liquidia falls after Insmed's TPIP meets endpoints in study

Sign Up For More Events
Sign Up For More Events
News
9.5
07-24PRnewswirePinnedInsmed to Host Second-Quarter 2025 Financial Results Conference Call on Thursday, August 7, 2025
3.0
07-15NASDAQ.COMINSM Quantitative Stock Analysis
6.5
07-10BenzingaCramer Says Tesla Dominates While Ouster Is 'Too Speculative'
Sign Up For More News
People Also Watch

HLI
Houlihan Lokey Inc
195.930
USD
-0.73%

SOLV
Solventum Corp
74.750
USD
+1.11%

ELS
Equity LifeStyle Properties Inc
59.630
USD
-0.47%

LAMR
Lamar Advertising Co
125.420
USD
+0.35%

SAIA
Saia Inc
333.610
USD
+7.00%

SUZ
Suzano SA
9.470
USD
+1.18%

JKHY
Jack Henry & Associates Inc
176.350
USD
-2.52%

PR
Permian Resources Corp
13.780
USD
+1.17%

REG
Regency Centers Corp
71.180
USD
-0.49%

JNPR
Juniper Networks Inc
0
USD
+0.05%
FAQ

What is Insmed Inc (INSM) stock price today?
The current price of INSM is 103.95 USD — it has increased 0.42 % in the last trading day.

What is Insmed Inc (INSM)'s business?

What is the price predicton of INSM Stock?

What is Insmed Inc (INSM)'s revenue for the last quarter?

What is Insmed Inc (INSM)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Insmed Inc (INSM)'s fundamentals?

How many employees does Insmed Inc (INSM). have?
